Share your research articles, interpretations and experiences here. Let us know how these studies affect you and your decisions.
Posted on: Mar 14, 2021 06:46PM
Olma61 wrote:Sortilin-related receptor is a druggable therapeutic target in breast cancer
“....Identifying alternative HER2-related therapeutic targets could offer means to overcome .... resistance mechanisms. We have previously demonstrated that an endosomal sorting protein, sortilin-related receptor (SorLA), regulates the traffic and signaling of HER2 and HER3, thus promoting resistance to HER2-targeted therapy in breast cancer. This study aims to assess the feasibility of targeting SorLA using a monoclonal antibody. Our results demonstrate that anti-SorLA antibody (SorLA ab) alters the resistance of breast cancer cells to HER2 monoclonal antibody trastuzumab in vitro and in ovo.“
“SorLA is a druggable target in breast cancer.“